Canadian Markets open in 7 hrs 16 mins

Titan Pharmaceuticals, Inc. (TTNP)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.950.00 (0.00%)
At close: 4:00PM EDT
People also watch
VNDABDSIIMUCONCSNAVB
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.95
Open2.95
Bid2.75 x 500
Ask3.05 x 1200
Day's Range2.90 - 3.00
52 Week Range2.70 - 8.74
Volume39,072
Avg. Volume88,838
Market Cap62.54M
Beta1.62
PE Ratio (TTM)14.68
EPS (TTM)0.2
Earnings DateMay 8, 2017 - May 12, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • Capital Cube10 days ago

    ETFs with exposure to Titan Pharmaceuticals, Inc. : April 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Titan Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to TTNP-US. Comparing the performance and risk of Titan Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cubelast month

    ETFs with exposure to Titan Pharmaceuticals, Inc. : March 27, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Titan Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to TTNP-US. Comparing the performance and risk of Titan Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Zacks Small Cap Researchlast month

    TTNP: 2016 Results; Deep Dive on Development Programs

    Titan Pharmaceuticals, Inc. (TTNP) reported full-year 2016 results on March 16, 2017 and later participated in an earnings call following the market close.  Total revenues, which consisted of a milestone payment and Probuphine royalties were $15.1 million compared to our estimates of $16.1 million.  The difference was due to fourth quarter royalty revenues of $35,000 vs. our estimates of $1.1 million.  R&D expenses of $6.1 million rose 31% over the prior year due to development expenses related to new ProNeura products. Free cash flow for 2016 was $6.1 million, generated by the $15 million in milestone payments by Braeburn in the second quarter paid upon FDA approval of Probuphine.  Cash levels increased over the year as a result of the positive cash flows from operations, from $7.9 million at the end of 2015 to $14.0 million at year end 2016.